Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 2,461,720 shares, a drop of 12.1% from the October 13th total of 2,800,014 shares. Based on an average daily volume of 294,067 shares, the short-interest ratio is presently 8.4 days. Approximately 7.8% of the shares of the stock are short sold.

Asterias Biotherapeutics (AST) opened at $2.40 on Thursday. Asterias Biotherapeutics has a 12-month low of $2.00 and a 12-month high of $5.80.

Asterias Biotherapeutics (NYSEAMERICAN:AST) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $1.25 million.

Several research analysts recently commented on the company. HC Wainwright set a $12.00 price target on Asterias Biotherapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 16th. ValuEngine lowered Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research report on Tuesday, October 10th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $9.19.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.